Alisporivir
Alisporivir (INN), or Debio 025, DEB025, (or UNIL-025) is a cyclophilin inhibitor.[1] Its structure is reminiscent of, and synthesized from ciclosporin.
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
ECHA InfoCard | 100.234.903 |
Chemical and physical data | |
Formula | C63H113N11O12 |
Molar mass | 1216.662 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
It inhibits cyclophilin A.[2] Alisporivir is not immunosuppressive.[3]
It is being researched for potential use in the treatment of hepatitis C.[4][5] It has also been investigated for Duchenne muscular dystrophy[1] and may have therapeutic potential in Alzheimer's disease.[6]
Alisporivir is under development by Debiopharm for Japan and by Novartis for the rest of the world (licence granted by Debiopharm) since February 2010.
References
- Reutenauer J, Dorchies OM, Patthey-Vuadens O, Vuagniaux G, Ruegg UT (October 2008). "Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy". British Journal of Pharmacology. 155 (4): 574–84. doi:10.1038/bjp.2008.285. PMC 2579666. PMID 18641676.
- Gallay, PA; Lin K. (15 February 2013). "Profile of alisporivir and its potential in the treatment of hepatitis C." Drug Design, Development and Therapy. 7: 105–115. doi:10.2147/DDDT.S30946. PMC 3578503. PMID 23440335.
- Ptak RG, Gallay PA, Jochmans D, et al. (April 2008). "Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent". Antimicrob. Agents Chemother. 52 (4): 1302–17. doi:10.1128/AAC.01324-07. PMC 2292519. PMID 18212100.
- Paeshuyse J, Kaul A, De Clercq E, et al. (April 2006). "The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro". Hepatology. 43 (4): 761–70. doi:10.1002/hep.21102. PMID 16557546. S2CID 45825453.
- Coelmont L, Kaptein S, Paeshuyse J, et al. (December 2008). "Debio 025, a cyclophilin binding molecule, is highly efficient in clearing HCV replicon containing cells, alone or when combined with Specifically Targeted Antiviral Therapy for HCV (STAT-C) inhibitors". Antimicrobial Agents and Chemotherapy. 53 (3): 967–76. doi:10.1128/AAC.00939-08. PMC 2650540. PMID 19104013.
- "USC study reveals potential new treatment target for Alzheimer's disease | Keck School of Medicine of USC". Retrieved 2021-06-16.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.